Literature DB >> 11809714

Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma.

Chao-Nan Qian1, Xiang Guo, Brian Cao, Eric J Kort, Chong-Chou Lee, Jindong Chen, Ling-Mei Wang, Wei-Yuan Mai, Hua-Qing Min, Ming-Huang Hong, George F Vande Woude, James H Resau, Bin Tean Teh.   

Abstract

Met tyrosine kinase, the receptor for HGF/SF, is important in various cellular functions, including proliferation, mitogenesis, formation of branching tubules, angiogenesis, and tumor cell invasion and metastasis. However, the role of Met/HGF signaling pathway in nasopharyngeal carcinoma (NPC) has not been evaluated. In this study, we determined the expression profile and clinical correlation of Met/HGF in 66 cases of advanced NPC and the activation mechanisms of Met receptor in five NPC cell lines. Immunofluorescent staining and quantitative image analysis showed that the Met protein was expressed throughout the tumors and normal nasopharyngeal epithelia. Compared with NPC, the Met expression level was higher in columnar nasopharyngeal epithelium but lower in squamous nasopharyngeal epithelium. The normal interstitial stromal tissue expressed the lowest level of Met protein. HGF was detected mainly in the normal interstitial tissue surrounding the tumor. Met protein expression level was inversely correlated with patients' survival time; the correlation coefficient was -0.319 (P = 0.009). The mean survival time was 118 months in low Met expression group versus 52 months in high expression group (P = 0.0004). The cumulative 5-year survival rate was 77.68% in low expression group versus 38.24% in high expression group. The clinical stage was also significantly more advanced in high Met expression group. In the multivariate analysis, both clinical stage and Met protein expression level were independent prognostic indicators for patient survival. All of the five NPC cell lines tested did not express hgf mRNA but expressed met mRNA, and tyrosine phosphorylation of Met protein was mainly induced by exogenous HGF stimulation in these cells. No mutation was found in the tyrosine kinase and the juxtamembrane domains of Met receptor in the five NPC cell lines tested. These results indicate that: (a) high Met protein expression level correlates with poorer survival in late-stage NPC and serves as an independent prognostic indicator; and (b) the Met receptor in NPC is activated by its paracrine ligand HGF from the interstitial tissues rather than by an autocrine loop or its activating mutation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11809714

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  Increased hepatocyte growth factor and c-Met receptor expression in nasopharyngeal carcinoma.

Authors:  Tian Luan; Yang Yu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  HGF/SF increases tumor blood volume: a novel tool for the in vivo functional molecular imaging of Met.

Authors:  Galia Tsarfaty; Gideon Y Stein; Sharon Moshitch-Moshkovitz; Dafna W Kaufman; Brain Cao; James H Resau; George F Vande Woude; Ilan Tsarfaty
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

3.  In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met.

Authors:  Sharon Moshitch-Moshkovitz; Galia Tsarfaty; Dafna W Kaufman; Gideon Y Stein; Keren Shichrur; Eddy Solomon; Robert H Sigler; James H Resau; George F Vande Woude; Ilan Tsarfaty
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

4.  Pharmacophore modeling and virtual screening studies to identify new c-Met inhibitors.

Authors:  Wenting Tai; Tao Lu; Haoliang Yuan; Fengxiao Wang; Haichun Liu; Shuai Lu; Ying Leng; Weiwei Zhang; Yulei Jiang; Yadong Chen
Journal:  J Mol Model       Date:  2011-12-28       Impact factor: 1.810

5.  Proteomic analysis to identify cytokeratin 18 as a novel biomarker of nasopharyngeal carcinoma.

Authors:  Xiang-Min Li; Wei-Guo Huang; Hong Yi; Ai-Lan Cheng; Zhi-Qiang Xiao
Journal:  J Cancer Res Clin Oncol       Date:  2009-06-16       Impact factor: 4.553

6.  Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer.

Authors:  Jun Yu; Kenoki Ohuchida; Kazuhiro Mizumoto; Nami Ishikawa; Yasuhiro Ogura; Daisuke Yamada; Takuya Egami; Hayato Fujita; Seiji Ohashi; Eishi Nagai; Masao Tanaka
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

7.  Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death.

Authors:  V W Y Lui; E Y L Wong; K Ho; P K S Ng; C P Y Lau; S K W Tsui; C-M Tsang; S-W Tsao; S H Cheng; M H L Ng; Y K Ng; E K Y Lam; B Hong; K W Lo; T S K Mok; A T C Chan; G B Mills
Journal:  Oncogene       Date:  2010-11-08       Impact factor: 9.867

8.  Targeting MET by tyrosine kinase inhibitor suppresses growth and invasion of nasopharyngeal carcinoma cell lines.

Authors:  Patrick C Lau; Elaine Y Wong
Journal:  Pathol Oncol Res       Date:  2011-08-25       Impact factor: 3.201

9.  Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.

Authors:  Kyung Hee Lee; Eun Young Choi; Myung Soo Hyun; Byung Ik Jang; Tae Nyeun Kim; Heon Ju Lee; Jong Yuel Eun; Hong Gin Kim; Sung Soo Yoon; Dong Sik Lee; Jung Hye Kim; Jae-Ryong Kim
Journal:  Clin Exp Metastasis       Date:  2007-11-09       Impact factor: 5.150

10.  PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.

Authors:  Hal E Crosswell; Anindya Dasgupta; Carlos S Alvarado; Tanya Watt; James G Christensen; Pradip De; Donald L Durden; Harry W Findley
Journal:  BMC Cancer       Date:  2009-11-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.